Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead program, KYV-101, is being advanced in late-stage trials for conditions such as myasthenia gravis, stiff person syndrome, and lupus nephritis, with additional exploration in multiple sclerosis.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaClinical-stage autologous cell therapy candidates designed to reset autoimmune disease activity.
Earlier-stage and additional indications built around the same autoimmune cell therapy platform.
Third-party cell manufacturing, release testing, and vector process development supporting trials.
Strategic alliances and licensing arrangements used to fund and extend the pipeline.
Asiakkaat
Kyverna does not yet sell approved products; its direct 'customers' are primarily clinical trial patients and the physicians, hospitals, and research centers running its studies. In a commercial setting, the company would ultimately serve specialty neurologists, rheumatologists, and transplant-style treatment centers that manage severe autoimmune disease. It also depends on contract manufacturers, research collaborators, and licensing partners to advance its programs.
Patients with autoimmune diseases enrolled in KYV-101 and related studies to evaluate safety and efficacy.
Hospitals, academic centers, and clinicians that recruit patients, administer protocols, and generate data.
Neurology and nephrology specialists who would drive adoption if the therapies are approved.
CMOs and vector suppliers that provide cell manufacturing, release testing, and process development.
Potential licensing or alliance partners that can provide capital, expertise, or commercialization support.
Strategia
Kyverna is focused on advancing KYV-101 through late-stage clinical development and preparing for regulatory filings, including support for a BLA in stiff person syndrome and a registrational Phase 3 trial in myasthenia gravis. At the same time, it is broadening the pipeline with KYV-102 and additional autoimmune indications while building the manufacturing, regulatory, and commercial infrastructure needed for a potential launch. Because the company remains pre-revenue, capital preservation and access to financing are central to execution.
Regulatory success depends on generating pivotal data in myasthenia gravis and stiff person syndrome.
A broader autoimmune portfolio reduces single-asset dependence and increases long-term value creation.
Cell therapies require specialized supply, release testing, and launch infrastructure before approval.
Maantiede
Kyverna is headquartered in the United States and its operating footprint is centered on U.S. clinical development and manufacturing support. The company uses third-party facilities in Pennsylvania for cell manufacturing and maintains office and laboratory space in Emeryville, California. It also has a supply relationship with Oxford Biomedica in the UK, which adds cross-border manufacturing and sourcing exposure.
Riskit
Kyverna is a pre-revenue biotech with a limited operating history, substantial accumulated losses, and ongoing dependence on external capital. Its value creation depends on successful clinical outcomes, regulatory approvals, and reliable third-party manufacturing, all of which are uncertain and can be delayed by scientific, operational, or macroeconomic factors.
- Clinical development failure or delayVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company’s value depends on positive data and timely enrollment in KYV-101 trials.
Kohdistuu - Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Late-stage programs must satisfy FDA and other regulators before commercialization can begin.
Kohdistuu - Financing and liquidity riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has recurring losses and may need equity, debt, or partnership funding to continue operations.
Kohdistuu: General corporate funding and trial execution
- Third-party manufacturing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Cell therapy supply relies on CMOs and vector partners, reducing control over quality, timing, and cost.
Kohdistuu - Competitive and IP riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Competing autoimmune therapies and patent challenges could reduce market opportunity and exclusivity.
Kohdistuu: Autoimmune cell therapy landscape
Kirjanpito
Harkinnanvaraiset erätClinical trial and manufacturing costs are recognized as incurred or estimated, affecting quarterly volatility.
Vaikutus: Trial timing can shift reported losses materially
Office, laboratory, and equipment leases create right-of-use assets and liabilities that affect leverage and cash commitments.
Vaikutus: Emeryville lab lease and equipment leases
Employee and director equity awards are a significant non-cash expense for a development-stage biotech.
Vaikutus: Impacts operating loss and comparability
Management’s runway estimates depend on future financing and spending plans.
Vaikutus: Important for assessing dilution and execution risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Taysha Gene Therapies, Inc.
TSHA · Biological Products, (No Diagnostic Substances)
Kiora Pharmaceuticals, Inc
KPHMW · Pharmaceutical Preparations
Päivitetty: 24.9.2026